Drug Trial Radar · NCT05489237
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
276
Actual
Start
Aug 3, 2022
Primary completion
Mar 10, 2027
Study completion Mar 26, 2027
Sponsor
- Lead sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLCIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Conditions
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumor (GIST)
- Digestive System Disease
- Gastrointestinal Diseases
- Metastatic Cancer
Interventions
IDRX-42Drug
Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)Time frame: When participant completes 1 cycle (28 days) treatment with safety and tolerability assessment by investigators
- Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)Time frame: Approximately 18 months from first participant enrolled
- Phase 1 (Dose Escalation) - Determination of the MTD and/or RP1bD(s) of orally administered IDRX-42Time frame: Approximately 18 months from first participant enrolled
- Phase 1 (Dose Escalation) - C-QTc sub-study: QTcF - concentration response analysisTime frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
- Phase 1b-Number of participants with TEAEs and with laboratory test resultsTime frame: Approximately 18 months
- Phase 1b - Objective Response Rate (ORR) mRESIST v1.1Time frame: Approximately 18 months
- Phase 1b - C-QTcF sub-study: QTcF - concentration response analysisTime frame: At the end of Cycle 1 Day 1 and at the end of Cycle 2 Day 1 (each cycle is 28 days)
Locations
31 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Beijing, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Wuhan, China
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Rotterdam, South Holland, Netherlands
GSK Investigational Site
Seongnam-si Gyeonggi-do, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.